Management of Early Node-Positive Breast Cancer in Australia: A Multicentre Study
To examine practice patterns for breast cancer patients with limited sentinel node (SN) disease in light of the ACOSOG Z0011 results. Retrospective analysis of patients with T1‐2 breast cancer and positive sentinel lymph node biopsy (SLNB) admitted between January 2009 and December 2012. Patient dem...
Gespeichert in:
| Veröffentlicht in: | The breast journal 2016-07, Vol.22 (4), p.413-419 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 419 |
|---|---|
| container_issue | 4 |
| container_start_page | 413 |
| container_title | The breast journal |
| container_volume | 22 |
| creator | Gannan, Emma Khoo, Jeremy Nightingale, Sophie Suhardja, Thomas Surya Lippey, Jocelyn Keane, Holly Tan, Kian Jin Clouston, David Gorelik, Alexandra Mann, Gregory Bruce |
| description | To examine practice patterns for breast cancer patients with limited sentinel node (SN) disease in light of the ACOSOG Z0011 results. Retrospective analysis of patients with T1‐2 breast cancer and positive sentinel lymph node biopsy (SLNB) admitted between January 2009 and December 2012. Patient demographics, tumor characteristics, and treatments were recorded. Eight hundred positive SLNBs were identified. A total of 452 (56.5%) proceeded to completion axillary lymph node dissection (cALND). cALND rate decreased from 65.1% to 49.7% from 2009–2010 to 2011–2012. cALND was performed for micrometastasis or isolated tumor cells in 39.3% in 2009–2010 and 22.2% in 2011–2012, whereas for macrometastases the rates were 83.1% and 68.6%, respectively. cALND rates diminished for both Z0011‐eligible and ‐ineligible patients. The ACOSOG Z0011 trial presentation and publication coincided with a reduction in cALND for breast cancer with limited nodal disease. There appears equipoise regarding management of macrometastatic SN disease. |
| doi_str_mv | 10.1111/tbj.12595 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1808688237</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1801431281</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5015-943d8947afc2f3043428947f3859681768e39d77cbd34ee235e6774ecf890b883</originalsourceid><addsrcrecordid>eNqNkE0vBEEQhjtCfCwHf0D6yGFsf073uK0Ni7CIFW6d3pkaaWZn6O7B_nvD4iZRl6pKnvc5vAhtU7JPu-nH6eM-ZTKTS2idSiYSoQRd7m6iZEIZu19DGyE8EkJYRsQqWmOKZJJruo6uL2xtH2AGdcRNiY-sr-Z43BSQXDXBRfcK-NCDDREPbZ2Dx67GgzZEbytnD_AAX7RVdHkX94BvYlvMN9FKaasAW9-7h26PjybDk-T8cnQ6HJwnuSRUJpnghc6EsmXOSk4EF-zzLbmWWaqpSjXwrFAqnxZcADAuIVVKQF7qjEy15j20u_A---alhRDNzIUcqsrW0LTBUE10qjXj6j8oFZwyTTt0b4HmvgnBQ2mevZtZPzeUmM-yTVe2-Sq7Y3e-te10BsUv-dNuB_QXwJurYP63yUwOz36UySLhQoT334T1TyZVXElzNx4ZMZGj8fWZMpJ_AI3KlTk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1801431281</pqid></control><display><type>article</type><title>Management of Early Node-Positive Breast Cancer in Australia: A Multicentre Study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Gannan, Emma ; Khoo, Jeremy ; Nightingale, Sophie ; Suhardja, Thomas Surya ; Lippey, Jocelyn ; Keane, Holly ; Tan, Kian Jin ; Clouston, David ; Gorelik, Alexandra ; Mann, Gregory Bruce</creator><creatorcontrib>Gannan, Emma ; Khoo, Jeremy ; Nightingale, Sophie ; Suhardja, Thomas Surya ; Lippey, Jocelyn ; Keane, Holly ; Tan, Kian Jin ; Clouston, David ; Gorelik, Alexandra ; Mann, Gregory Bruce ; Melbourne Breast Group ; The Melbourne Breast Group</creatorcontrib><description>To examine practice patterns for breast cancer patients with limited sentinel node (SN) disease in light of the ACOSOG Z0011 results. Retrospective analysis of patients with T1‐2 breast cancer and positive sentinel lymph node biopsy (SLNB) admitted between January 2009 and December 2012. Patient demographics, tumor characteristics, and treatments were recorded. Eight hundred positive SLNBs were identified. A total of 452 (56.5%) proceeded to completion axillary lymph node dissection (cALND). cALND rate decreased from 65.1% to 49.7% from 2009–2010 to 2011–2012. cALND was performed for micrometastasis or isolated tumor cells in 39.3% in 2009–2010 and 22.2% in 2011–2012, whereas for macrometastases the rates were 83.1% and 68.6%, respectively. cALND rates diminished for both Z0011‐eligible and ‐ineligible patients. The ACOSOG Z0011 trial presentation and publication coincided with a reduction in cALND for breast cancer with limited nodal disease. There appears equipoise regarding management of macrometastatic SN disease.</description><identifier>ISSN: 1075-122X</identifier><identifier>EISSN: 1524-4741</identifier><identifier>DOI: 10.1111/tbj.12595</identifier><identifier>PMID: 27095381</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>ACOSOG Z0011 trial ; Aged ; Antineoplastic Agents - therapeutic use ; Australia ; Axilla - pathology ; Axilla - surgery ; axillary lymph node dissection ; breast cancer ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Clinical Trials as Topic ; Female ; Humans ; Lymph Node Excision - statistics & numerical data ; Lymph Nodes - pathology ; Lymphatic Metastasis - pathology ; Middle Aged ; Neoplasm Micrometastasis - pathology ; Retrospective Studies ; sentinel lymph node biopsy ; Sentinel Lymph Node Biopsy - statistics & numerical data</subject><ispartof>The breast journal, 2016-07, Vol.22 (4), p.413-419</ispartof><rights>2016 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5015-943d8947afc2f3043428947f3859681768e39d77cbd34ee235e6774ecf890b883</citedby><cites>FETCH-LOGICAL-c5015-943d8947afc2f3043428947f3859681768e39d77cbd34ee235e6774ecf890b883</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Ftbj.12595$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Ftbj.12595$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27095381$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gannan, Emma</creatorcontrib><creatorcontrib>Khoo, Jeremy</creatorcontrib><creatorcontrib>Nightingale, Sophie</creatorcontrib><creatorcontrib>Suhardja, Thomas Surya</creatorcontrib><creatorcontrib>Lippey, Jocelyn</creatorcontrib><creatorcontrib>Keane, Holly</creatorcontrib><creatorcontrib>Tan, Kian Jin</creatorcontrib><creatorcontrib>Clouston, David</creatorcontrib><creatorcontrib>Gorelik, Alexandra</creatorcontrib><creatorcontrib>Mann, Gregory Bruce</creatorcontrib><creatorcontrib>Melbourne Breast Group</creatorcontrib><creatorcontrib>The Melbourne Breast Group</creatorcontrib><title>Management of Early Node-Positive Breast Cancer in Australia: A Multicentre Study</title><title>The breast journal</title><addtitle>Breast J</addtitle><description>To examine practice patterns for breast cancer patients with limited sentinel node (SN) disease in light of the ACOSOG Z0011 results. Retrospective analysis of patients with T1‐2 breast cancer and positive sentinel lymph node biopsy (SLNB) admitted between January 2009 and December 2012. Patient demographics, tumor characteristics, and treatments were recorded. Eight hundred positive SLNBs were identified. A total of 452 (56.5%) proceeded to completion axillary lymph node dissection (cALND). cALND rate decreased from 65.1% to 49.7% from 2009–2010 to 2011–2012. cALND was performed for micrometastasis or isolated tumor cells in 39.3% in 2009–2010 and 22.2% in 2011–2012, whereas for macrometastases the rates were 83.1% and 68.6%, respectively. cALND rates diminished for both Z0011‐eligible and ‐ineligible patients. The ACOSOG Z0011 trial presentation and publication coincided with a reduction in cALND for breast cancer with limited nodal disease. There appears equipoise regarding management of macrometastatic SN disease.</description><subject>ACOSOG Z0011 trial</subject><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Australia</subject><subject>Axilla - pathology</subject><subject>Axilla - surgery</subject><subject>axillary lymph node dissection</subject><subject>breast cancer</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Clinical Trials as Topic</subject><subject>Female</subject><subject>Humans</subject><subject>Lymph Node Excision - statistics & numerical data</subject><subject>Lymph Nodes - pathology</subject><subject>Lymphatic Metastasis - pathology</subject><subject>Middle Aged</subject><subject>Neoplasm Micrometastasis - pathology</subject><subject>Retrospective Studies</subject><subject>sentinel lymph node biopsy</subject><subject>Sentinel Lymph Node Biopsy - statistics & numerical data</subject><issn>1075-122X</issn><issn>1524-4741</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE0vBEEQhjtCfCwHf0D6yGFsf073uK0Ni7CIFW6d3pkaaWZn6O7B_nvD4iZRl6pKnvc5vAhtU7JPu-nH6eM-ZTKTS2idSiYSoQRd7m6iZEIZu19DGyE8EkJYRsQqWmOKZJJruo6uL2xtH2AGdcRNiY-sr-Z43BSQXDXBRfcK-NCDDREPbZ2Dx67GgzZEbytnD_AAX7RVdHkX94BvYlvMN9FKaasAW9-7h26PjybDk-T8cnQ6HJwnuSRUJpnghc6EsmXOSk4EF-zzLbmWWaqpSjXwrFAqnxZcADAuIVVKQF7qjEy15j20u_A---alhRDNzIUcqsrW0LTBUE10qjXj6j8oFZwyTTt0b4HmvgnBQ2mevZtZPzeUmM-yTVe2-Sq7Y3e-te10BsUv-dNuB_QXwJurYP63yUwOz36UySLhQoT334T1TyZVXElzNx4ZMZGj8fWZMpJ_AI3KlTk</recordid><startdate>201607</startdate><enddate>201607</enddate><creator>Gannan, Emma</creator><creator>Khoo, Jeremy</creator><creator>Nightingale, Sophie</creator><creator>Suhardja, Thomas Surya</creator><creator>Lippey, Jocelyn</creator><creator>Keane, Holly</creator><creator>Tan, Kian Jin</creator><creator>Clouston, David</creator><creator>Gorelik, Alexandra</creator><creator>Mann, Gregory Bruce</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>201607</creationdate><title>Management of Early Node-Positive Breast Cancer in Australia: A Multicentre Study</title><author>Gannan, Emma ; Khoo, Jeremy ; Nightingale, Sophie ; Suhardja, Thomas Surya ; Lippey, Jocelyn ; Keane, Holly ; Tan, Kian Jin ; Clouston, David ; Gorelik, Alexandra ; Mann, Gregory Bruce</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5015-943d8947afc2f3043428947f3859681768e39d77cbd34ee235e6774ecf890b883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>ACOSOG Z0011 trial</topic><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Australia</topic><topic>Axilla - pathology</topic><topic>Axilla - surgery</topic><topic>axillary lymph node dissection</topic><topic>breast cancer</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Clinical Trials as Topic</topic><topic>Female</topic><topic>Humans</topic><topic>Lymph Node Excision - statistics & numerical data</topic><topic>Lymph Nodes - pathology</topic><topic>Lymphatic Metastasis - pathology</topic><topic>Middle Aged</topic><topic>Neoplasm Micrometastasis - pathology</topic><topic>Retrospective Studies</topic><topic>sentinel lymph node biopsy</topic><topic>Sentinel Lymph Node Biopsy - statistics & numerical data</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gannan, Emma</creatorcontrib><creatorcontrib>Khoo, Jeremy</creatorcontrib><creatorcontrib>Nightingale, Sophie</creatorcontrib><creatorcontrib>Suhardja, Thomas Surya</creatorcontrib><creatorcontrib>Lippey, Jocelyn</creatorcontrib><creatorcontrib>Keane, Holly</creatorcontrib><creatorcontrib>Tan, Kian Jin</creatorcontrib><creatorcontrib>Clouston, David</creatorcontrib><creatorcontrib>Gorelik, Alexandra</creatorcontrib><creatorcontrib>Mann, Gregory Bruce</creatorcontrib><creatorcontrib>Melbourne Breast Group</creatorcontrib><creatorcontrib>The Melbourne Breast Group</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>The breast journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gannan, Emma</au><au>Khoo, Jeremy</au><au>Nightingale, Sophie</au><au>Suhardja, Thomas Surya</au><au>Lippey, Jocelyn</au><au>Keane, Holly</au><au>Tan, Kian Jin</au><au>Clouston, David</au><au>Gorelik, Alexandra</au><au>Mann, Gregory Bruce</au><aucorp>Melbourne Breast Group</aucorp><aucorp>The Melbourne Breast Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of Early Node-Positive Breast Cancer in Australia: A Multicentre Study</atitle><jtitle>The breast journal</jtitle><addtitle>Breast J</addtitle><date>2016-07</date><risdate>2016</risdate><volume>22</volume><issue>4</issue><spage>413</spage><epage>419</epage><pages>413-419</pages><issn>1075-122X</issn><eissn>1524-4741</eissn><abstract>To examine practice patterns for breast cancer patients with limited sentinel node (SN) disease in light of the ACOSOG Z0011 results. Retrospective analysis of patients with T1‐2 breast cancer and positive sentinel lymph node biopsy (SLNB) admitted between January 2009 and December 2012. Patient demographics, tumor characteristics, and treatments were recorded. Eight hundred positive SLNBs were identified. A total of 452 (56.5%) proceeded to completion axillary lymph node dissection (cALND). cALND rate decreased from 65.1% to 49.7% from 2009–2010 to 2011–2012. cALND was performed for micrometastasis or isolated tumor cells in 39.3% in 2009–2010 and 22.2% in 2011–2012, whereas for macrometastases the rates were 83.1% and 68.6%, respectively. cALND rates diminished for both Z0011‐eligible and ‐ineligible patients. The ACOSOG Z0011 trial presentation and publication coincided with a reduction in cALND for breast cancer with limited nodal disease. There appears equipoise regarding management of macrometastatic SN disease.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>27095381</pmid><doi>10.1111/tbj.12595</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1075-122X |
| ispartof | The breast journal, 2016-07, Vol.22 (4), p.413-419 |
| issn | 1075-122X 1524-4741 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1808688237 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | ACOSOG Z0011 trial Aged Antineoplastic Agents - therapeutic use Australia Axilla - pathology Axilla - surgery axillary lymph node dissection breast cancer Breast Neoplasms - pathology Breast Neoplasms - therapy Clinical Trials as Topic Female Humans Lymph Node Excision - statistics & numerical data Lymph Nodes - pathology Lymphatic Metastasis - pathology Middle Aged Neoplasm Micrometastasis - pathology Retrospective Studies sentinel lymph node biopsy Sentinel Lymph Node Biopsy - statistics & numerical data |
| title | Management of Early Node-Positive Breast Cancer in Australia: A Multicentre Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T19%3A17%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20Early%20Node-Positive%20Breast%20Cancer%20in%20Australia:%20A%20Multicentre%20Study&rft.jtitle=The%20breast%20journal&rft.au=Gannan,%20Emma&rft.aucorp=Melbourne%20Breast%20Group&rft.date=2016-07&rft.volume=22&rft.issue=4&rft.spage=413&rft.epage=419&rft.pages=413-419&rft.issn=1075-122X&rft.eissn=1524-4741&rft_id=info:doi/10.1111/tbj.12595&rft_dat=%3Cproquest_cross%3E1801431281%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1801431281&rft_id=info:pmid/27095381&rfr_iscdi=true |